SCHEMBL201903

SCHEMBL201903

COC(=O)C(NC(=O)c1ccc(-c2cc(F)cc(F)c2)cc1)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 5/20 0.41
MLYCD O95822 1/20 0.41
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC4 P56524 1/20 0.38
MAOB P27338 1/20 0.38
ABCB1 P08183 3/20 0.37
ABCC1 P33527 3/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 1/20 0.37
PTPN1 P18031 1/20 0.37
CYP26A1 O43174 1/20 0.37
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
ROCK2 O75116 1/20 0.36
CYP2C9 P11712 1/20 0.36
PRKACA P17612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL200955 0.83 ANPEP (0.51) ANPEP
SCHEMBL200965 0.80 HDAC1 (0.43) MLYCDHDAC1HDAC6HDAC4CTSL
SCHEMBL202434 0.80 TAS1R3 (0.57) MLYCDALDH1A1TAS1R3TAS1R1CTSS
SCHEMBL203558 0.80 RAB9A (0.54) ALDH1A1TAS1R3TAS1R1GAA
SCHEMBL13266878 0.73 KMT2A (0.55) HDAC1HDAC6HDAC4
SCHEMBL201374 0.72 ANPEP (0.54) ANPEPHDAC3HDAC1HDAC2HDAC8
SCHEMBL30147551 0.72 HDAC6 (0.52) ANPEPHDAC3HDAC1HDAC2HDAC8
SCHEMBL254376 0.70 CA2 (0.43) MLYCDHDAC1ALDH1A1CYP3A4CYP26A1
SCHEMBL21082225 0.70 ALDH1A1 (0.47) ALDH1A1CYP3A4CYP26A1ROCK2PRKACA
SCHEMBL19534377 0.70 ALDH1A1 (0.47) ALDH1A1CYP3A4CYP26A1ROCK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 ANPEP 418/4885MLYCD 1614/4885HDAC3 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.